Nasopharyngeal Diseases  >>  docetaxel  >>  Phase 2
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
docetaxel / Generic mfg.
NCT00055770: Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer

Completed
2
45
US
erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, docetaxel, RP 56976, Taxotere, TXT, laboratory biomarker analysis, pharmacological study, pharmacological studies
National Cancer Institute (NCI)
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
12/06
 
NCT00565448 / 2007-001211-33: Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents

Completed
2
75
Europe, RoW
docetaxel, Taxotere®, XRP6976, cisplatin, 5-fluorouracil, 5-FU
Sanofi
Nasopharyngeal Neoplasms, Carcinoma
03/09
01/12
NCT00436293: Taxotere + Cisplatin in Nasopharyngeal Carcinoma

Completed
2
61
RoW
Docetaxel, Cisplatin
Sanofi
Nasopharyngeal Neoplasms
03/10
03/10
NCT01596868: GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China

Completed
2
60
RoW
gemcitabine and cisplatin, GP, docetaxel and cisplatin, TP
Air Force Military Medical University, China
Nasopharyngeal Squamous Cell Carcinoma, Toxicity Due to Radiotherapy
10/13
10/13
CADEN, NCT00953420: Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes

Completed
2
20
US
Docetaxel, Taxotere, Carboplatin, Paraplatin, Dexamethasone, Decadron, EBV-specific cytotoxic T lymphocytes, EBV-specific cytotoxic T lymphocytes 1 x 10e8 cells/m2 IV, G-CSF or Peg-GCSF, Filgrastim or pegylated filgrastim
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine, M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma
06/14
07/15
NCT01326559: Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)

Completed
2
33
RoW
Docetaxel, Cisplatin, 5-FU and Cetuximab
Hong Kong Nasopharyngeal Cancer Study Group Limited, The University of Hong Kong, Sanofi, Merck Sharp & Dohme LLC, Roche Pharma AG
Nasopharyngeal Carcinoma
12/16
03/17
NCT02035527: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed
1/2
3
US
sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, cisplatin, CACP, CDDP, CPDD, DDP, docetaxel, RP 56976, Taxotere, TXT, Correlative Studies, laboratory biomarker analysis
Ohio State University Comprehensive Cancer Center, National Comprehensive Cancer Network
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
04/17
04/17

Download Options